Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

361 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Active surveillance for prostate cancer: the role of the pathologist.
Delahunt B, Hammond E, Egevad L, Samaratunga H, Srigley JR, Humphrey PA, Rubin M, Epstein JI, Lin DW, Gore JL, Nacey JN, Klotz L, Sandler H, Zietman AL, Holden S, Montironi R, Evans AJ, McKenney JK, Berney D, Wheeler TM, Chinnaiyan AM, True L, Knudsen B, Amin MB. Delahunt B, et al. Among authors: zietman al. Pathology. 2015 Jan;47(1):1-3. doi: 10.1097/PAT.0000000000000186. Pathology. 2015. PMID: 25474525 No abstract available.
Selective bladder preservation by trimodality therapy for patients with muscularis propria-invasive bladder cancer and who are cystectomy candidates--the Massachusetts General Hospital and Radiation Therapy Oncology Group experiences.
Shipley WU, Zietman AL, Kaufman DS, Coen JJ, Sandler HM. Shipley WU, et al. Among authors: zietman al. Semin Radiat Oncol. 2005 Jan;15(1):36-41. doi: 10.1016/j.semradonc.2004.07.008. Semin Radiat Oncol. 2005. PMID: 15662605 Review.
Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
Kupelian P, Kuban D, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A. Kupelian P, et al. Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):415-9. doi: 10.1016/j.ijrobp.2004.05.018. Int J Radiat Oncol Biol Phys. 2005. PMID: 15667961
Increasing external beam dose for T1-T2 prostate cancer: effect on risk groups.
Thames HD, Kuban DA, DeSilvio ML, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Zietman AL. Thames HD, et al. Among authors: zietman al. Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):975-81. doi: 10.1016/j.ijrobp.2006.02.043. Epub 2006 Jun 5. Int J Radiat Oncol Biol Phys. 2006. PMID: 16750319
Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy.
Kaufman DS, Winter KA, Shipley WU, Heney NM, Wallace HJ 3rd, Toonkel LM, Zietman AL, Tanguay S, Sandler HM. Kaufman DS, et al. Among authors: zietman al. Urology. 2009 Apr;73(4):833-7. doi: 10.1016/j.urology.2008.09.036. Epub 2008 Dec 18. Urology. 2009. PMID: 19100600 Clinical Trial.
361 results